PRESS RELEASE 2002

• 5-ASAs/mesalazine May Lower Colorectal Cancer Risk in Inflammatory Bowel Disease (IBD)

By pulse in PRESS RELEASE 2002 on 08 November 2002

More evidence that taking your medication does a body good: Results of a recent study from the UK suggests that Inflammatory Bowel Disease patients (IBD) who take their 5-ASA/mesalazine medicine…

• Ferring Pharmaceuticals and Beth Israel Deaconess Medical Center Announce Drug Discovery Collaboration Agreement

By pulse in PRESS RELEASE 2002 on 31 October 2002

COPENHAGEN, DK. and BOSTON, MASS. — Ferring Pharmaceuticals and Beth Israel Deaconess Medical Center (BIDMC) today announced they have signed a collaborative agreement to…

• Ferring and Johnson & Johnson Join in a Research Collaboration

By pulse in PRESS RELEASE 2002 on 30 October 2002

Ferring announced today that it will collaborate with Ortho-McNeil Pharmaceuticals Inc. (Ortho-McNeil) and Ortho-McNeil’s research affiliate, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)…

• Ferring appoints new Board member

By pulse in PRESS RELEASE 2002 on 02 October 2002

The Board of Directors of Ferring announced this week that Professor Michael Rosenblatt has been appointed to the Group Board…

• Ferring Appoints New Vice-President of Global Marketing

By pulse in PRESS RELEASE 2002 on 01 October 2002

Ferring would like to announce that Mr. Aaron Graff has been appointed as Vice President of Global Marketing, Medical Services and Business Development…

• Taking the Needle Out of the Injection

By pulse in PRESS RELEASE 2002 on 16 May 2002

Ferring Launches a New No Needle Device at 2nd Ferring International Paediatric Endocrinology Symposium…

• Ferring Appoints New Board Member

By pulse in PRESS RELEASE 2002 on 13 May 2002

The Board of Directors of Ferring announced today that Mr. Bernd Wolff has been appointed as a board member. Wolff becomes an outside director to the board…

• FDA APPROVES BRAVELLE™ (urofollitropin for injection, purified)

By pulse in PRESS RELEASE 2002 on 06 May 2002

Ferring Pharmaceuticals, a world leader in naturally occurring protein hormones, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Bravelle™…

• Building for the 21st Century

By pulse in PRESS RELEASE 2002 on 21 March 2002

The new Ferring International Center in Copenhagen will be officially inaugurated by the Danish Minister for Science, Technology and Innovation and renowned architect Henning Larsen on Thursday, March 21st, 2002…

• Advances In Infertility

By pulse in PRESS RELEASE 2002 on 23 January 2002

International infertility experts convened at a congress today to preview the newest scientific findings in infertility and to discuss better ways to meet increasing demands from infertile couples for more effective treatments…